BAS Annual Virtual Meeting 2021

Thursday 16 – Friday 17 September 2021
Virtual

Why attend our BAS meeting?

The BAS audience is consisted of both clinicians and basic scientists with interest in atherosclerosis and it’s mechanisms.

Abstract submission

Abstract submissions are encouraged from BAS ordinary, junior and student members.

Submitted abstracts will be shortlisted for oral presentation at the Early Career Investigator competition, oral presentation at the single cell workshop as well as a moderated poster session.

Abstract submission deadline extension | Submission now closed

PROGRAMME

Thursday 16 September | 10:00 – 20:00 hrs
Friday 17 September | 09:00 – 16:00 hrs

Vascular Ageing and Hypertension – towards new targets for treatments

Organised by
Professor Tomas GUZIK, Professor Sheila FRANCIS + Dr Helle JORGENSEN

Hugh Sinclair lecture
Catherine Boileau

Chairperson:  Charis Antoniades (BAS) 

Exploring Familial Hypercholesterolaemia – the journey of PCSK9 | Prof Catherine BOILEAU, Paris, FRANCE


SESSION 1: 
Hypertension – state of the art

Co-chairs:  Michael Holmes (BAS) + Tomasz Guzik (BAS) 

Hypertension and genomics
Prof Sir Mark CAULFIELD, London, UK

Hypertension and Immunity
Prof David HARRISON, Vanderbilt, USA

SESSION 2: 
Vascular Smooth muscle cells, ageing and cardiovascular disease 

Co-chairs: Endre Kiss-Toth( BAS) + Mandy Grootaert ( BAS) 

Vascular smooth muscle cell ageing and calcification
Prof Cathy SHANAHAN,London, UK

Novel insights into premature ageing and atherosclerosis
Prof Vicente ANDRES, Madrid, SPAIN

Clonal expansion of SMCs and atherosclerosis
Prof Jacob Fog BENTZON, Aarhus, DENMARK

SESSION 3: 
Early career investigator awards

Sponsored by:

Cardiovascular research sponsor

Co-chairs: Tomasz Guzik (BAS) + Murray Clarke (BAS)

SESSION 4: 
The intersection between inflammation and coagulation

Co-chairs: Sheila Francis (BAS) + Inhye Park (BAS)

Interleukin-1 alpha, coagulation and inflammation
Dr Murray CLARKE, Cambrdge, UK

Crosstalk between platelets and Immunity
Prof Steffen MASSBERG, Munich, GERMANY

SESSION 5: 
Emerging interventions for hypertension 

Co-chairs: Ric Cubbon (BAS) + Tomasz Guzik ( BAS) 

Pharmacological and non-pharmacological targets of hypertension
Prof Markus SCHLAICH, Perth, AUSTRALIA

Precision medicine and cardiovascular disease
Prof Dame Anna DOMINICZAK, Glasgow, UK

Periodontal therapy in hypertensive patients
Prof Tomasz GUZIK, Glasgow, UK

NEW
Young BAS Community session – Inspiring Career Talk and questions

Co-chairs: Inhye Park (BAS) + Mandy Grootaert (BAS)

This is a new initiative created by, and for young scientists.
Its mission is to bring young scientists from the cardiovascular field together thereby increasing the outreach of the BAS in the UK and beyond.  
The inaugural session will have an exciting career talk from Dr Helle JORGENSEN (Cambridge, UK). 

Moderated poster session

Sponsored by:

British Journal of Pharmacology
Symposium: 
Single cell-RNA sequencing Symposium  

Friday 17 September | 13:00 – 16:00 hrs

Cell Atlas Technologies to Study Vasculature and Inflammation
Dr Sarah TEICHMANN (Cambridge, UK)

2 oral presentations selected from submitted abstracts.    

Workshop led by 10X and Miltenyi Biotec on latest development in single cell analysis, sample prep guide and hands-on data analysis.

Sponsored by:

Registration

Registration offers access to all the sessions and on demand for one month following the meeting.

BAS members (Ordinary, Honorary, Senior) | £50.00
Student BAS members | £0.00
Junior BAS members | £25.00
Non BAS Society members (Healthcare professionals, scientists, researchers, trainees) | £90.00
Industry (Pharma, diagnostic and other commercial companies) | £125.00

Sponsors

Silver Sponsor

Prof Vicente Andrés

Prof Vicente Andrés PhD
Full Professor
Laboratory of Molecular and Genetic Cardiovascular Pathophysiology
Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC)
Madrid
Spain

Dr. Andrés obtained his PhD in Biological Sciences (University Barcelona, 1990), and received postdoctoral training at Children’s Hospital, Harvard University (1991-1994) and St. Elizabeth’s Medical Center, Tufts University (1994-1995). In 1995, he was appointed Assistant Professor of Medicine at Tufts Univ, and returned to Spain in 1999 to establish his research group at the Institute of Biomedicine of Valencia-CSIC. In 2009, he moved to Madrid to lead the laboratory of Molecular and Genetic Cardiovascular Pathophysiology in the CNIC, where he holds the position of Director of Basic Research Department since 2015. His lab has identified cell cycle and transcription factors that regulate atherosclerosis & restenosis and biomarkers of these diseases, and has unveiled genetic, cellular and molecular mechanisms underlying physiological and premature aging and associated cardiovascular disease (CVD). His translational research program provides a framework for understanding how genes and environmental factors dictate aging and CVD with the ultimate goal of improving diagnosis and treatment.

As an acknowledgement of his long internationally-recognized scientific career, Dr. Andrés received the Dr. León Dumont Prize 2010 from the Belgian Society of Cardiology. His pioneering work on progeria was rewarded in 2014 with an Established Investigator Award from the Progeria Research Foundation (PRF) and he is member of its Medical Research Committee since 2015.

Prof Markus Schlaich

Dobney Chair in Clinical Research
Dobney Hypertension Centre
School of Medicine – Royal Perth Hospital Unit
Faculty of Medicine, Dentistry & Health Sciences | The University of Western Australia

Professor Schlaich is a renal physician and a European Society of Hypertension (ESH) accredited hypertension specialist with a strong background in clinical research. His main scientific interests focus on pathophysiologic aspects of hypertension, involvement of the kidneys, and hypertension mediated organ damage. Professor Schlaich has a specific interest in treatment modalities targeting the sympathetic nervous system and has contributed to the development of renal denervation and carotid body modulation as alternative therapeutic approaches for hypertension, and more recently hepatic denervation for modulation of glucose metabolism. He has authored more than 400 articles and book chapters in peer reviewed journals and has received several research prizes and awards including the ESH Björn Folkow Award for outstanding contribution to original research in hypertension. He currently serves as President of the High Blood Pressure Research Council of Australia and is on the Scientific Council of the International Society of Hypertension for which he previously served as treasurer. He is a founding member of the European Society of Hypertension Working Group on Interventional Treatment of Hypertension. He serves on the Editorial Board of Hypertension, Journal of Hypertension, andCurrent Hypertension Reports. He has been involved in guideline development both nationally (2016 Heart Foundation Guidelines) and internationally (2020 ISH Global Hypertension Practice Guidelines). He is passionate about educating the next generation of clinician researchers and has received the inaugural Mentorship Award from the Royal Perth Hospital.

Prof Sir Mark Caulfield

Prof Mark CaulfieldMD FRCP FESC FHonPharm FBHS FMedSci
Chief Executive Officer (CEO)
Barts Life Sciences 
London

Sir Mark Caulfield graduated in Medicine in 1984 from the London Hospital Medical College and trained in Clinical Pharmacology at St Bartholomew’s Hospital where he developed a research programme in molecular genetics of hypertension, which has discovered over 1000 gene loci for blood pressure.

He was Director of the William Harvey Research Institute between 2002 and 2020 and was elected a Fellow of the Academy of Medical Sciences in 2008. Since 2008 he directs the National Institute for Health Research Cardiovascular Biomedical Research Unit and Centre at Barts. Between 2010 and 2015 he co-led the merger of three hospitals in North London to create the new £400 million Barts Heart Centre.

He has won the Lily Prize of the British Pharmacology Society, the Bjorn Folkow Award of the European Society of Hypertension 2016 and the Franz Volhard Award of the International Society of Hypertension in 2018.

In 2013 he became an NIHR Senior Investigator and was Chief Scientist for Genomics England (100,000 Genomes Project) between 2013 until 2021. Sir Mark was awarded a Knighthood in the June 2019 Queen’s Birthday Honours List for services to the 100,000 Genomes Project. He cocreated the National Genomic Test Directory and the Genomic Medicine Service bringing equity of access to genomic testing across 56 million people.

Sir Mark is now Chief Executive of Barts Life Sciences, which is a £600 million Life Science expansion of Queen Mary University of London, Barts Health, and industrial partnerships in 1 million square feet of space in Whitechapel.

Dr Sarah Teichmann

Head of Cellular Genetics
Wellcome Sanger Institute
Cambridge

Sarah Teichmann is interested in global principles of regulation of gene expression and protein complexes, with a focus on immunity. Sarah did her PhD at the MRC Laboratory of Molecular Biology, Cambridge, UK and was a Beit Memorial Fellow at University College London. She started her group at the MRC Laboratory of Molecular Biology in 2001, discovering stereotypical pathways of assembly and evolution of protein complexes during this time. In 2013, she moved to the Wellcome Genome Campus in Hinxton/Cambridge, jointly with the EMBL-European Bioinformatics Institute and the Wellcome Sanger Institute (WSI). In February 2016 she became Head of the Cellular Genetics Programme at the WSI and co-founded the Human Cell Atlas international initiative which she continues to lead. Sarah was elected a member of EMBO in 2012, a fellow of the Academy of Medical Sciences in 2015 and a fellow of the Royal Society in 2020.

Dr Murray Clarke

Dr Murray ClarkeBHF Senior Fellow
Department of Cardiovascular Medicine
The University of Cambridge, Addenbrooke’s Hospital
Cambridge, UK

Murray is a BHF Senior Fellow with extensive experience in cardiovascular, cell death and immunology research. For the last 12 years he has been running a research group whose interests lie in understanding the downstream consequences of cell death, how this influences innate and adaptive immunity, and how this affects cardiovascular disease. His group has a strong interest in the apical inflammatory cytokine IL-1, and they have identified novel molecular mechanisms that control its activation and signalling, and how aberration of these processes drive immune dysfunction in vivo. The group also have a strong interest in cellular senescence and how IL-1α drives senescent cell-associated inflammation, which is pivotal in multiple diseases. A thorough understanding of the basic mechanisms controlling IL-1 will enable rational targeting of its disease promoting activities without compromising its vital role in host defence.

Prof. David G. Harrison

Dr HarrisonM.D.
Betty and Jack Bailey Professor of Medicine
Pharmacology and Molecular Physiology and Biophysics
Vanderbilt University Medical Center, USA

Dr. Harrison is the Betty and Jack Bailey Professor of Medicine, Pharmacology and Molecular Physiology and Biophysics at Vanderbilt University Medical Center. He received his MD degree from the University of Oklahoma in 1974 and obtained his house staff and clinical cardiology training at Duke University. From 1980-82, he completed a cardiovascular research fellowship at the University of Iowa. In 1982, he joined the faculty at the University of Iowa, and was promoted to Associate Professor in 1987. In 1990, he joined Emory University, where he was appointed Professor of Medicine.  From 2000 to 2009, Dr. Harrison served as the Director of Cardiology at Emory. In January of 2011, Dr. Harrison became the Director of the Division of Clinical Pharmacology, Vanderbilt University School of Medicine.

His career has been devoted to basic research related to vascular function, the practice of cardiology and the education of young physicians. Dr. Harrison has been an Established Investigator of the American Heart Association and has served on numerous committees for the AHA, served as the Chairman of the American Heart Association Council on Circulation, and served as Chairman of the National Institutes of Health Experimental Cardiovascular Studies Study Section (ECS). Dr. Harrison has served on the editorial boards of multiple journals and has given numerous invited and named lectures.  He has received several awards most notable are the 2004 Novartis award from the American Heart Association for outstanding research in hypertension, the Robert Berne Award from the Cardiovascular Section of the American Physiology Society (APS), the Carl Wiggers Award from the APS for outstanding research in cardiovascular physiology, the 2010 Distinguished Scientist Award at the annual meeting of the American Heart Association (AHA) and most recently, the 2018 Basic Science award from the American Heart Association for “lasting contributions that changed the direction of research in hypertension and its complications.”

Prof Jacob Fog Bentzon, 

Prof Jacob Fog Bentzon

MD, PhD
Full professor, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain
Professor of Experimental Atherosclerosis, Aarhus University, Aarhus, Denmark

Jacob Fog Bentzon is group leader at CNIC, Madrid, Spain, and Professor of Experimental Atherosclerosis Research at Aarhus University, Denmark. Together with a cross-institutional group of researchers and students, he studies disease mechanisms in atherosclerosis and develops research tools for that field. Recent achievements include techniques to induce atherosclerosis in mice and minipigs, re-assessment of clinical imaging techniques for atherosclerosis, and the identification of new atherogenic disease mechanisms.

His interest in atherosclerosis was sparked during medical school where he trained in experimental research with Professor Erling Falk at Aarhus University, Denmark. After graduating, he returned to the Falk lab in 2004 to complete a PhD on the cellular biology of atherosclerosis. He subsequently did a postdoc in genetic engineering before starting as an independent researcher in 2010.

Jacob Fog Bentzon has published 67 papers in the field of atherosclerosis and is on the editorial board for ATVB and JACC. The team is funded mainly from the European Research Council (Consolidator grant), the Novo Nordisk Foundation (Hallas Møller Ascending Investigator grant), the La Caixa Foundation and the Spanish Ministry of Science and Innovation.

Prof Catherine M Shanahan

Prof Catherine M ShanahanPhD
Professor of Cellular Signaling
Vice Dean (Development, Diversity and Inclusion) FoLSM
School of Cardiovascular Medicine and Sciences
King’s College London, London, UK

Professor Shanahan was educated in Australia and obtained a PhD in Genetics from the University of Adelaide. She began research in the field of cardiovascular medicine in the Biochemistry Department at the University of Cambridge UK.  From 1995-2004 she was a British Heart Foundation Lecturer and in 2005 became a BHF Senior Fellow in the Department of Medicine, University of Cambridge.  In 2007 she left Cambridge to take up the Chair of Cellular Signalling in the School of Cardiovascular Medicine and Sciences at King’s College London and is currently Section Head for Vascular Biology.

Professor Shanahan’s work focuses on mechanisms of vascular smooth muscle cell (VSMC) dysfunction in ageing and disease and she performed pioneering work in the area of vascular calcification. She has published over 200 articles, reviews and book chapters.

She is a member of the British Atherosclerosis Society, British Society of Cardiovascular Research, European Vascular Biology Organisation and North America Vascular Biology Organisation and serves on the Editorial Boards of Circulation Research and Arteriosclerosis, Thrombosis and Vascular Biology.  She is also Vice-Dean of Development, Diversity and Inclusion for the Faculty of Life Sciences and Medicine.